Skip to Main Content
Contribute Try STAT+ Today

When people get tested for genes that might expose them to an increased risk of cancer, that analysis generally looks at DNA alone. Now, what’s being billed as the first commercial test of its kind aims to turn up more at-risk patients by also looking at DNA’s cousin: RNA, which carries out orders for making proteins.

The new +RNAinsight test, launched this week by Ambry Genetics, will screen RNA transcripts for 18 genes, including the BRCA genes known for variants that elevate risk for breast and ovarian cancer, alongside the usual DNA analysis. For now, insurers won’t pay anything additional for the RNA testing to be added the Ambry DNA tests that they already cover; the combined testing will cost $400 for the tiny fraction of Ambry’s patients who pay entirely out of pocket.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.